胸腺肽α1对多重耐药鲍曼不动杆菌肺炎的临床疗效

摘要

Objective To research the clinical effect of thymosin alpha-1 on pneumonia patients with muti-drug resistant acinetobacter haumannii. Methods 40 pneumonia patients with muti-drug resistant acinetobacter baumannii were randomly divided into two groups: the treatment group and the control group. All patients were given the conventional therapy, and the treatment group received 1. 6 mg of thymosin alpha-1 through subcutaneous injection once a day for a week, and then twice a week for four weeks. The duration of mechanical ventilation and hospital stay at intensive care unit was recorded, and the clinical effect was evaluated. The levels of procalcitonin ( PCT ), hs-CRP and white blood cell ( WBC ) were tested between the two groups. Results The duration of mechanical ventilation and hospital stay at ICU were significantly shorter in the treatment group than in the control group. The improvement of total cure rate and mortality was more pronounced in the treatment group than in the control group. The levels of PCT, hs-CRP, and WBC decreased more obviously in the treatment group than in the control group with statistical significance. Conclusion Thymosin alpha-1 can improve the immune status of pneumonia patients with muti-drug resistant acinetobacter baumannii pneumonia, reduce the level of inflammation, and enhance the curative effect of anti-infection.%目的 研究胸腺肽α1对多重耐药鲍曼不动杆菌肺炎患者临床疗效的影响.方法 将40例多重耐药鲍曼不动杆菌肺炎患者随机分为治疗组和对照组,对照组给予常规治疗,治疗组在常规治疗的同时,加用胸腺肽α1,皮下注射1.6 mg,每天1次,应用一周后,改为2次/周,应用4周.统计两组的机械通气时间、ICU住院时间、评价临床疗效;测定两组降钙素原(PCT)、超敏C-反应蛋白(hs-CRP)、白细胞数(WBC)水平.结果 与对照组相比,治疗组机械通气时间VS、ICU住院时间 VS 明显缩短;总有效率提高,病死率降低(P<0.05) ;在炎症指标方面,胸腺肽治疗组PCT、hs-CRP、WBC值均低于对照组,差异有统计学意义.结论 胸腺肽α1可以改善多重耐药鲍曼不动杆菌肺炎患者的自身免疫状况,降低炎症水平,提高抗感染治疗的效果.